Sort   by:  
 Page size 
UnknownClinical, environmental, and genetic risk factors for substance use disorders: characterizing combined effects across multiple cohorts.
Not available
S-EPMC9938102 | biostudies-literature
Unknown20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Not available
S-EPMC5734609 | biostudies-literature
UnknownPosttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.
Not available
S-EPMC11294800 | biostudies-literature
UnknownA Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
Not available
S-EPMC7781100 | biostudies-literature
UnknownPathogenic UNC13A variants cause a neurodevelopmental syndrome by impairing synaptic function.
Not available
S-EPMC12597829 | biostudies-literature
UnknownGenetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge.
Not available
S-EPMC2922003 | biostudies-literature
UnknownGenetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed.
Not available
S-EPMC9075703 | biostudies-literature
UnknownGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
Not available
S-EPMC3182531 | biostudies-literature
UnknownEfficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
Not available
S-EPMC8700279 | biostudies-literature
UnknownResponses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
Not available
S-EPMC9334931 | biostudies-literature
Sort   by:  
 Page size